Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Issue 2 (6th April 2018)

• Record Type: Journal Article
• Authors: DeFronzo, Ralph A.; Ferrannini, Ele; Schernthaner, Guntram; Hantel, Stefan; Elsasser, Ulrich; Lee, Christopher; Hach, Thomas; Lund, Søren S.
• Is Part Of: Endocrinology, diabetes & metabolism. Volume 1:Issue 2(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-04-06
• Subjects: blood glucose -- glycosylated haemoglobin A -- sodium‐glucose transporter 2; Endocrinology -- Periodicals; Diabetes -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1002/edm2.16
• Languages: English
• ISSNs: 2398-9238

Abstract

Summary: Aims: To analyse the effect of baseline glycated haemoglobin (HbA1c ) on the reduction in HbA1c with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Materials and methods: Using regression analyses of individual patient data from two Phase III studies, we compared the change in HbA1c according to a unit change in baseline HbA1c (the slope) with empagliflozin 10 mg or 25 mg vs sitagliptin (monotherapy) after 24 weeks, and with empagliflozin 25 mg vs glimepiride (as add‐on to metformin) after 52 weeks. Results: Steeper slopes of HbA1c decline were observed with empagliflozin 10 or 25 mg vs sitagliptin monotherapy at week 24. Regression analysis showed slopes of −0.59 (95% CI −0.70, −0.47), −0.49 (95% CI −0.62, −0.37) and −0.29 (95% CI −0.42, −0.15) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively ( P < .001 and P < .05 for empagliflozin 10 mg and empagliflozin 25 mg, respectively, vs sitagliptin). Similarly, a steeper slope of HbA1c decline was observed with empagliflozin 25 mg vs glimepiride as add‐on to metformin at week 52. Regression analysis showed slopes of − 0.52 (95% CI −0.59, −0.44) and −0.32 (95% CI −0.39, −0.25) for empagliflozin 25 mg and glimepiride, respectively ( P < .001 for empagliflozin 25 mg vs glimepiride). Conclusions: Incremental reductions in HbA1c with increasing baseline HbA1c are greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Abstract : These analyses assessed the effect of baseline HbA1c on the reduction in HbA1c with empagliflozin compared with sitagliptin or glimepiride (Figure) in patients with type 2 diabetes, using regression analyses of individual patient data from two Phase III studies. Incremental reductions in HbA1c with increasing baseline HbA1c were greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.